Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 9032 results

  1. Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

    In development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  3. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 February 2027

    NICE guideline
    In development

  4. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 15 June 2026.

    Technology appraisal guidance
    In consultation

  5. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  11 September 2026

    NICE guideline
    In development

  6. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672

    In development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Tislelizumab with platinum-based chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer at high risk of recurrence [ID6708]

    Awaiting development Reference number: GID-TA11953 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development Reference number: GID-TA11216 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

    Topic prioritisation

    Topic prioritisation

  10. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

    Topic prioritisation

    Topic prioritisation

  11. Bismuth subcitrate potassium–metronidazole–tetracycline hydrochloride with omeprazole for treating Helicobacter pylori and preventing peptic ulcer relapse [TSID11900]

    Topic prioritisation

    Topic prioritisation

  12. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date:  02 December 2026

    In development

  13. Surgical mesh for treatment of primary ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date:  03 February 2027

    In development

  14. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTE10090 Expected publication date:  10 March 2027

    In development

  15. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTE10079 Expected publication date:  04 February 2027

    In development